## Supporting information

## Peptide-based pH-sensitive Antibacterial Hydrogel for Drug-

## resistant Biofilm-infected Diabetic Wounds Healing

Duoyang Fan,<sup>a, b</sup> Ruyan Xie, <sup>a, b</sup> Xiaohui Liu, <sup>a, b</sup> Haohan Li, <sup>a, b</sup> Ziheng Luo, <sup>a, b</sup> Yanbing Li, <sup>c</sup> Fei Chen, \*<sup>a, b</sup> <sup>b</sup> and Wenbin Zeng \*<sup>a, b</sup>

<sup>a</sup> Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, PR China.

<sup>b</sup> Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha, 410013, PR China.

<sup>c</sup> Xiangya Hospital of Central South University, Changsha, PR China.

 Table S1. Composition and nomenclature of hydrogels.

Sample	c <sub>TPI-PN</sub> (mg/mL)
QCS-OD	0
QCS-OD-AMP (COA-T0)	0
QCS-OD-AMP/TPI-PN0.05 (COA-T1)	0.05
QCS-OD-AMP/TPI-PN0.10 (COA-T2)	0.10
QCS-OD-AMP/TPI-PN0.15 (COA-T3)	0.15
QCS-OD-AMP/TPI-PN0.20 (COA-T4)	0.20
QCS-OD-AMP/TPI-PN0.25 (COA-T5)	0.25



**Figure S1**. Synthesis and FT-IR characterization of ODex and QCS. (a) Synthesis of ODex; (b) synthesis of QCS; (c) FT-IR spectra of dextran and ODex; (D) FT-IR spectra of chitosan and QCS.



**Figure S2**. (a) **COA-T3** before and after gelation. (b) Photographs of the hydrogels: (i) **QCS-OD**, (ii) **COA-T0**, (iii) **COA-T1**, (iv) **COA-T2**, (v) **COA-T3**. (c) Photographs of the adhesiveness of **COA-T3** to different materials. (d) Original state (i), compressed state (ii), and the recovered state (iii) of the prepared hydrogel.



Figure S3. Amplitude scanning assay of QCS-OD (a), COA-T0 (b), COA-T1 (c), COA-T2 (d), COA-T3 (e).



**Figure S4**. Investigation of ROS generation of **COA-T3**. (a) The fluorescence emission spectrum of DCFH with excitation wavelength of 488nm under different illumination time in the presence of **COA-T3**. (b) The fluorescence emission intensity of DCFH at 525nm increased gradually with the prolongation of illumination time. (c) The UV-vis absorption spectrum of ABDA under different illumination time in the presence of **COA-T3**. (d) The absorption value of ABDA at 378nm decreased with the prolongation of light time.



**Figure S5**. Effect of different concentration of photosensitizer in hydrogels on its antibacterial activity. (a) The colony growth of *E.coli*, *MDRE.coli*, *S.aureus* and *MRSA* on agar plates after hydrogels treatment with different concentrations of photosensitizer with or without light irradiation. The survival rates of *E.coli* (b), *MDRE.coli* (c), *S.aureus* (d) and *MRSA* (e) in hydrogels with different concentrations of photosensitizers were quantified by counting the colonies on agar plates. The data is displayed as the mean  $\pm$ SD (n = 3). \*\*\*\**P* < 0.0001; \*\*\**P* < 0.001; \*\*\**P* < 0.01; "ns" represents no significant difference between the two groups.



**Figure S6.** CLSM images of *S. aureus* and *E. coli* after incubation with PBS (Control) or **COA-T3** and then co-staining with Hoechst 33342 (blue fluorescence, a nucleic acid dye for all bacteria) and YO-PRO-1 (green fluorescence, a dye for dead bacteria). Scale bar: 10 μm.



**Figure S7.** CLSM images of *MRSA* and *MDR E. coli* after incubation with PBS (Control) or **COA-T3** and then co-staining with Hoechst 33342 (blue fluorescence, a nucleic acid dye for all bacteria) and YO-PRO-1 (green fluorescence, a dye for dead bacteria). Scale bar: 10 µm.



**Figure S8**. Anti-biofilm assays. CLSM 3D and side view imaging of *MRSA*-biofilms co-incubation with PBS or **COA-T3** before and after biofilm formation. The samples were co-staining with Hoechst 33342 (blue fluorescence) and YO-PRO-1 (green fluorescence) before CLSM imaging. Scale bars: 50 μm.



**Figure S9.** Investigation of biofilm (24 h) inhibition/disruption *via* crystal violet staining method. (a-b) Images of *MRSA* stained by crystal violet after different treatments. (c-d) Biofilm biomass of *MRSA* after different treatments.



Figure S10. Investigation of biofilm (48 h) inhibition/disruption *via* crystal violet staining method. (a-b) Images of *MRSA* stained by crystal violet after different

treatments. (c-d) Biofilm biomass of MRSA after different treatments.



**Figure S11.** Investigation of biofilm (72 h) inhibition/disruption *via* crystal violet staining method. (a-b) Images of *MRSA* stained by crystal violet after different treatments. (c-d) Biofilm biomass of *MRSA* after different treatments.



Figure S12. Representative images of H&E-stained heart, liver, spleen, lung and kidney slices from mice 8 days post treatment at each group. Scale bar:  $200 \mu m$ .